{"id":"rifaximin-oral-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Flatulence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifaximin is a rifamycin-class antibiotic that acts locally in the gastrointestinal tract by inhibiting bacterial RNA polymerase, thereby suppressing the growth of gram-positive and gram-negative enteric bacteria. Because it is minimally absorbed systemically, it achieves high local concentrations in the gut while maintaining low systemic exposure, making it suitable for treating intestinal infections and conditions driven by dysbiosis.","oneSentence":"Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:12.194Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Traveler's diarrhea caused by non-invasive strains of Escherichia coli"},{"name":"Hepatic encephalopathy"},{"name":"Irritable bowel syndrome with diarrhea (IBS-D)"}]},"trialDetails":[{"nctId":"NCT07285785","phase":"PHASE4","title":"Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2026-02-11","conditions":"Diarrhea, Gastroenteritis, Bacterial Infection","enrollment":54},{"nctId":"NCT05159427","phase":"PHASE1","title":"Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2022-03-15","conditions":"Human Gastrointestinal Physiology Data","enrollment":40},{"nctId":"NCT07454408","phase":"PHASE1, PHASE2","title":"Evaluation of the Outcome of Fecal Microbiota Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2026-03-07","conditions":"Hepatic Encephalopathy, Fecal Microbiota Transplantation, TIPS","enrollment":40},{"nctId":"NCT04244877","phase":"PHASE3","title":"Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility","status":"WITHDRAWN","sponsor":"MetroHealth Medical Center","startDate":"2021-09-15","conditions":"Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth","enrollment":""},{"nctId":"NCT06058572","phase":"PHASE2","title":"Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-08-02","conditions":"Acute Leukemia","enrollment":166},{"nctId":"NCT05453916","phase":"PHASE1, PHASE2","title":"Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2022-07-01","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":""},{"nctId":"NCT06312683","phase":"PHASE4","title":"Rifaximin for the Secondary Prevention of Recurrent Pouchitis","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-07-01","conditions":"Pouchitis","enrollment":16},{"nctId":"NCT05408910","phase":"PHASE2, PHASE3","title":"Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2025-07","conditions":"Cystic Fibrosis, Abdominal Pain, Small Bowel Disease","enrollment":""},{"nctId":"NCT07037394","phase":"PHASE4","title":"A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Qurratul Ain Jamil","startDate":"2024-12-02","conditions":"Overt Hepatic Encephalopathy","enrollment":252},{"nctId":"NCT06852274","phase":"NA","title":"Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study","status":"COMPLETED","sponsor":"Dr. Amjad Khan","startDate":"2023-03-01","conditions":"Diverticular Diseases, Gastro-Intestinal Disorder","enrollment":70},{"nctId":"NCT04073290","phase":"PHASE4","title":"Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2020-01-21","conditions":"Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension","enrollment":238},{"nctId":"NCT05587036","phase":"PHASE2, PHASE3","title":"Effects of Rifaximin on Gut Microbiota and Emotion","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-02-02","conditions":"Healthy Volunteers, Stress, Fear","enrollment":60},{"nctId":"NCT01846663","phase":"PHASE4","title":"Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-04-03","conditions":"Hepatic Encephalopathy","enrollment":6},{"nctId":"NCT05621005","phase":"PHASE2","title":"Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients","status":"COMPLETED","sponsor":"Samar Atef Sebaweh Mohammed","startDate":"2019-03-01","conditions":"Ascites Infection","enrollment":104},{"nctId":"NCT03557788","phase":"PHASE4","title":"Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2018-05-07","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":33},{"nctId":"NCT05083572","phase":"PHASE4","title":"Effect of Probiotic on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2021-03-10","conditions":"Dysbiosis","enrollment":32},{"nctId":"NCT03712280","phase":"PHASE2","title":"MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2018-12-01","conditions":"Hepatic Cirrhosis, Hepatic Encephalopathy (HE)","enrollment":50},{"nctId":"NCT04118699","phase":"PHASE2","title":"Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial","status":"UNKNOWN","sponsor":"Yokohama City University","startDate":"2019-12-25","conditions":"Chronic Intestinal Pseudo-obstruction","enrollment":12},{"nctId":"NCT01355575","phase":"PHASE4","title":"Rifaximin in Fatty Liver Disease","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2011-05","conditions":"Nonalcoholic Fatty Liver Disease, NAFLD, Nonalcoholic Steatohepatitis","enrollment":15},{"nctId":"NCT04074421","phase":"PHASE4","title":"Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-10","conditions":"IBS - Irritable Bowel Syndrome, Gut Microbiota","enrollment":240},{"nctId":"NCT03962283","phase":"PHASE2, PHASE3","title":"Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2019-08-02","conditions":"Small Bowel Disease, Rifaximin","enrollment":78},{"nctId":"NCT02498418","phase":"PHASE3","title":"Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-01-06","conditions":"Diarrhea","enrollment":739},{"nctId":"NCT00743912","phase":"PHASE1","title":"Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-09","conditions":"Pharmacokinetic","enrollment":24},{"nctId":"NCT00298038","phase":"PHASE3","title":"A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-12-19","conditions":"Hepatic Encephalopathy","enrollment":299},{"nctId":"NCT02240121","phase":"PHASE3","title":"One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2014-08-21","conditions":"Crohn's Disease","enrollment":80},{"nctId":"NCT02240108","phase":"PHASE3","title":"One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2014-10-28","conditions":"Crohn's Disease","enrollment":81},{"nctId":"NCT01842581","phase":"PHASE4","title":"The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-01-08","conditions":"Hepatic Encephalopathy, Cirrhosis","enrollment":222},{"nctId":"NCT00686920","phase":"PHASE3","title":"Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-03-07","conditions":"Hepatic Encephalopathy","enrollment":322},{"nctId":"NCT02637167","phase":"PHASE2","title":"GutHeart: Targeting Gut Microbiota to Treat Heart Failure","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2016-03-11","conditions":"Systolic Heart Failure","enrollment":150},{"nctId":"NCT02920242","phase":"PHASE3","title":"A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.","status":"TERMINATED","sponsor":"Sandoz","startDate":"2016-12-15","conditions":"Travelers' Diarrhea","enrollment":28},{"nctId":"NCT02738905","phase":"EARLY_PHASE1","title":"Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease","status":"WITHDRAWN","sponsor":"Jason Stubbs, MD","startDate":"2016-01","conditions":"End Stage Renal Disease","enrollment":""},{"nctId":"NCT01466595","phase":"PHASE2","title":"Rifaximin as a Modulator of Microbial Translocation and Immune Activation","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-09","conditions":"HIV-1 Infection","enrollment":73},{"nctId":"NCT02158182","phase":"PHASE4","title":"Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding","status":"COMPLETED","sponsor":"Hospital General de Mexico","startDate":"2014-07","conditions":"Hepatic Encephalopathy","enrollment":88},{"nctId":"NCT02019784","phase":"PHASE4","title":"Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2015-01","conditions":"Liver Cirrhosis, Hepatoencephalopathy, Early Fatal Progressive","enrollment":38},{"nctId":"NCT01769040","phase":"PHASE4","title":"Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Copenhagen University Hospital, Hvidovre","startDate":"2012-11","conditions":"Liver Cirrhosis, Ascites","enrollment":54},{"nctId":"NCT02334163","phase":"PHASE2","title":"The Effects of Nitazoxanide in Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-12","conditions":"Hepatic Encephalopathy","enrollment":36},{"nctId":"NCT00979056","phase":"PHASE3","title":"Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin","status":"COMPLETED","sponsor":"Dr. Philipp Zanger, MD MSc DTM","startDate":"2009-10","conditions":"Diarrhoea","enrollment":258}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["L-105","Sugar Pill"],"phase":"marketed","status":"active","brandName":"Rifaximin oral tablet","genericName":"Rifaximin oral tablet","companyName":"Yokohama City University","companyId":"yokohama-city-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria. Used for Traveler's diarrhea caused by non-invasive strains of Escherichia coli, Hepatic encephalopathy, Irritable bowel syndrome with diarrhea (IBS-D).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}